Jubilant Pharmova Ltd

Q1 FY27Pharmaceuticals & Biotechnology

Jubilant Pharmova Ltd Q1 FY27 Results & Presentation Highlights: Revenue, Margins & Order Book

Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.

Price₹1,064

Market cap₹17.0K Cr

P/E43.7

Updated24 Sept 2026

Read5 min read

Based on Jubilant Pharmova Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Overall Q1’FY27 revenue: Rs. Q1’FY27 Financials: - Revenue: Rs.

From Jubilant Pharmova Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

- Overall Q1’FY27 revenue: Rs. 2,229 Cr., up 17% YoY (Page 97) - CRDMO Drug Discovery revenue: Rs. 174 Cr., up 8% YoY (Page 96, 56) - CRDMO API revenue: Rs. 135 Cr., down 4% YoY (Page 96, 61) - Generics revenue: Rs. 173 Cr., up 4% YoY (Page 67) - Allergy Immunotherapy revenue: Rs. 214 Cr., up 18% YoY (Page 39) - Radiopharmacy revenue: Rs. 700 Cr., up 17% YoY (Page 32) - Radiopharmaceuticals revenue: Rs. 322 Cr., up 19% YoY (Page 23) Explicit outlook: - Expect revenue growth to continue healthily with steady margins (Page 96) - Generic margins expected to improve in subsequent quarters (Page 67)

2 more points management made on revenue & sales performance

Profitability & Margins

Q1’FY27 Financials:
Revenue: Rs. 2,229 Cr. (up 17% YoY)
EBITDA: Rs. 268 Cr. (down 11% YoY)
EBITDA Margin: 11.9% (down 385 bps YoY)
Reported PAT: Rs. 56 Cr. (down 45% YoY)
Reported PAT Margin: 2.5% (down 285 bps YoY)
Margin Outlook:
EBITDA margins expected to improve in H2 FY27 as production at CMO Montreal stabilizes.

2 more points management made on profitability & margins

See what Jubilant Pharmova Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

PET Manufacturing Facilities: Expanding from 3 to 9 sites; USD 60+ Mn investment; fully operational by FY28 (Page 34).
CDMO Sterile Injectables:
Montreal Line 5 (New Isolator Fill & Finish Line): Production started for SPECT; remediation ongoing; commercial batch expected Q2’FY27; operational FY29 (Pages 44, 50).
Spokane Line 4: Installation complete; technology transfer revenue expected from Q4’FY27; peak revenue in 3.5 years, USD 80-90 Mn potential (Pages 44, 49).
Spokane Line 3: Commercial batch production expected FY27; revenue scaling up; peak in 3.5 years, USD 80-90 Mn potential (Page 48).
Allergy Immunotherapy Facility Upgrade (Page 78).
Drug Discovery Services: Expansion at Greater Noida and new Devanahalli, Bengaluru site; capacity growth from 1,000 FTE (FY25) to 4,000 FTE (FY30); total Capex USD 150 Mn; expected RoCE >20% (Page 59).

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential

1KRM Ayurveda Ltd₹664 Cr

Rev 1Mar 1

2Accretion Pharmaceuticals Ltd₹239 Cr

Rev 1Mar 2

3₹18.3K Cr

Rev 1Mar 3

4₹6.5K Cr

Rev 1Mar 3

5₹33 Cr

Rev 1Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

The presentation mentions net debt increased from Rs. 1,952 Cr. on March 31, 2026, to Rs. 2,338 Cr. on June 30, 2026, leading to an increase in Net Debt/EBITDA from 1.5x to 1.8x (Page 78).
There is no explicit mention of any new fundraising through debt or equity in the disclosed content.
Long-term capex creditors remained nearly steady at Rs. 711 Cr. (Mar 31, 2026) and Rs. 710 Cr. (Jun 30, 2026) (Page 78).

2 more points management made on fundraising & capital structure

See what Jubilant Pharmova Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation reports the following about order book and related metrics: - At Spokane facility, after launch of the third Sterile Fill & Finish line (Line 3) in Q2’FY26, the company is ramping up revenues from technology transfer programs. - Currently, 10+ products across multiple formats and vial sizes are undergoing technology transfer on Line 3. - A strong order book pipeline is being built for Line 4; installation is complete. - Technology transfer revenues from Line 4 are expected to start in Q4’FY27, with full utilization in about 3.5 years.

2 more points management made on order book & pipeline

Jubilant Pharmova Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹2.3K Cr, net profit ₹119 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Jubilant Pharmova Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Beta Drugs Ltd (Q1 FY27)
Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32). Key investor presentation takeaways from Beta Drugs Ltd's Q1
NGL Fine Chem Ltd (Q1 FY27)
Quarterly Revenue (Q1FY27):** ₹139.16 crores . Key investor presentation takeaways from NGL Fine Chem Ltd's Q1 FY27 investor presentation — and how it ranks aga
Shree Ganesh Remedies Ltd (Q1 FY27)
Q1FY27 Revenue from Operations: ₹14.36 Cr . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q1 FY27 investor presentation — and how it rank
Anuh Pharma Ltd (Q1 FY27)
193.81 Cr, up 3.93% YoY from Rs. Key investor presentation takeaways from Anuh Pharma Ltd's Q1 FY27 investor presentation — and how it ranks against sector peer

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Jubilant Pharmova Ltd Q1 FY27 results?

Overall Q1’FY27 revenue: Rs. Q1’FY27 Financials: - Revenue: Rs.

What is Jubilant Pharmova Ltd share price analysis?

Jubilant Pharmova Ltd currently shows a neutral. The stock trades at a P/E of 43.7 with a market cap of ₹16,972 Cr. Investors should review the full earnings analysis for detailed insights.

Is Jubilant Pharmova Ltd planning capital expenditure?

PET Manufacturing Facilities: Expanding from 3 to 9 sites; USD 60+ Mn investment; fully operational by FY28 (Page 34). - CDMO Sterile Injectables: - Montreal Line 5 (New Isolator Fill & Finish Line): Production started for SPECT; remediation ongoing; commercial batch expected Q2’FY27; operational FY29 (Pages 44, 50). - Spokane Line 4: Installation complete; technology transfer revenue expected from Q4’FY27; peak revenue in 3.5 years, USD 80-90 Mn potential (Pages 44, 49). - Spokane Line 3: Commercial batch production expected FY27; revenue scaling up; peak in 3.5 years, USD 80-90 Mn potential (Page 48). - Allergy Immunotherapy Facility Upgrade (Page 78). - Drug Discovery Services: Expansion at Greater Noida and new Devanahalli, Bengaluru site; capacity growth from 1,000 FTE (FY25) to 4,000 FTE (FY30); total Capex USD 150 Mn; expected RoCE >20% (Page 59). - Capex Credits reported around Rs.

Keep Jubilant Pharmova Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Revenue & Sales Performance

Profitability & Margins

Capital Expenditure Plans

Top-ranked in Pharmaceuticals & Biotechnology

Fundraising & Capital Structure

Order Book & Pipeline

Jubilant Pharmova Ltd — Quarterly revenue & net profit

Continue your research

What Jubilant Pharmova Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Frequently Asked Questions